About Urovant

Our Mission

Urovant Sciences is a global biopharmaceutical company focused on developing novel therapies for urologic conditions.

Urovant’s lead therapeutic candidate is vibegron (RVT-901), an investigational oral β3-adrenergic agonist being developed for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

We plan to initiate an international Phase 3 program for vibegron in 2017. We also intend to expand our pipeline in urologic diseases in the future.

urovant-sciences-logo-mark

Copyright 2017 © All Rights Reserved